Palamar JJ
Department of Population Health, NYU Grossman School of Medicine, New York, USA.
ArticlePsilocybin
Psilocybin use, mental health treatment utilization, and unmet treatment need among US individuals with depression.
ArticleKetamine
Monitoring of Clinics That Use Direct-to-Consumer Advertising for Off-Label Ketamine in the New York Metropolitan Area: A Cross-Sectional Systematic Web Search.
ArticleKetamine
Considering unintentional exposure when testing for cocaine use via oral fluid testing.
ArticleKetamine
Differentiating intentional ketamine use from unintentional exposure as an adulterant using oral fluid testing.
ArticlePsilocybin
Prevalence and Correlates of Past-Year Psilocybin Use in the United States.
ArticleMDMA
Surface swabbing of nightclub venues to monitor the presence of cocaine, ketamine, and MDMA.
ArticleMDMA
Detection of Party Drugs on Mobile Phones in Relation to Self-Reported Use and Oral Fluid Detection Among NYC Nightclub Attendees.
ArticlePsychedelics
Substance Use Patterns Across the Sexual Identity Spectrum Among U.S. Individuals.
ArticleMDMA
An Update on the Epidemiology of Tusi ("Pink Cocaine").
ArticleMDMA
Trends in Past-Year Use of Poppers Among New York City Nightclub Attendees, 2017-2024.
ArticlePsychedelics
The Epidemiology of Recreational Use and Availability of DOC and DOI in the United States.
ArticleKetamine
Trends in nonmedical ketamine use, poisonings, related deaths, pharmaceutical diversions, and law enforcement seizures: results from annual population-based repeated cross-sectional studies.
ArticleMDMA
Exposures to synthetic cathinones, fentanyl, and xylazine among nightclub attendees in New York City, 2024.
ArticleKetamine
Trends in ketamine use among nightclub attendees in New York City, 2017-2024.
ArticleMDMA
Tusi use among the New York City nightclub-attending population.
ArticleMDMA
Prevalence and Correlates of Lifetime Ecstasy/MDMA Use Among Asian American and Pacific Islander Adult Populations in the United States, 2015-2020.
ArticleMDMA
Ecstasy, molly, MDMA: What health practitioners need to know about this common recreational drug.
ArticleKetamine
Trends in poisonings involving ketamine in the United States, 2019-2023.
ArticleKetamine
Trends and characteristics in ketamine use among US adults with and without depression, 2015-2022.
ArticleKetamine
The Rapidly Shifting Ketamine Landscape in the US.
ArticleMDMA
Increases in the use of drug testing kits among nightclub and festival attendees in New York City who use ecstasy, 2017-2022.
ArticlePsilocybin
National and regional trends in seizures of shrooms (psilocybin) in the United States, 2017-2022.
ArticleMDMA
Five cases of unintentional exposure to BZO-4en-POXIZID among nightclub attendees in New York City.
ArticleMDMA
Trends in reported and biologically confirmed drug use among people who use ecstasy in the nightclub/festival-attending population, 2016-2022.
ArticleMDMA
Trends and correlates of discordant reporting of drug use among nightclub/festival attendees, 2019-2022.
ArticlePsilocybin
Seasonal Variation of Use of Common Psychedelics and Party Drugs Among Nightclub/Festival Attendees in New York City.
ArticleKetamine
Trends in Illicit Ketamine Seizures in the US From 2017 to 2022.
ArticleMDMA
Prevalence and Correlates of Past Year Ecstasy/MDMA Use in the United States.
ArticleKetamine
Tusi: a new ketamine concoction complicating the drug landscape.
ArticleMDMA
Adverse drug effects as a deterrent against willingness to use in the future among nightclub/festival attendees.
ArticleMDMA
Prevalence of self-reported adverse effects associated with drug use among nightclub and festival attendees, 2019-2022.
ArticlePsilocybin
Trends in drug use among nightclub and festival attendees in New York City, 2017-2022.
ArticleMDMA
Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults.
ArticleKetamine
Trends in Ketamine Use, Exposures, and Seizures in the United States up to 2019.
ArticleKetamine
Test-retest reliability and cross-cultural applicability of DSM-5 adopted diagnostic criteria for ketamine use disorders.
ArticleMDMA
Media coverage about medical benefits of MDMA and ketamine affects perceived likelihood of engaging in recreational use.
ArticleMDMA
Virtual raves and happy hours during COVID-19: New drug use contexts for electronic dance music partygoers.
ArticleMDMA
Shifts in Unintentional Exposure to Drugs Among People Who Use Ecstasy in the Electronic Dance Music Scene, 2016-2019.
ArticleKetamine
Underreporting of drug use among electronic dance music party attendees.
ArticleMDMA
Trends in drug use among electronic dance music party attendees in New York City, 2016-2019.
ArticleKetamine
Extensive Underreported Exposure to Ketamine Among Electronic Dance Music Party Attendees.
ArticlePsilocybin
A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines.
ArticleMDMA
Adverse drug-related effects among electronic dance music party attendees.
ArticlePsychedelics
Use of new and uncommon synthetic psychoactive drugs among a nationally representative sample in the United States, 2005-2017.
ArticleDMT
Trends in DMT and other tryptamine use among young adults in the United States.
ArticleMDMA
Shifting characteristics of ecstasy users ages 12-34 in the United States, 2007-2014.
ArticlePsychedelics
Assessing self-reported use of new psychoactive substances: The impact of gate questions.
ArticleDMT
Correlates of new psychoactive substance use among a self-selected sample of nightclub attendees in the United States.
ArticleMDMA
Self-reported use of novel psychoactive substances among attendees of electronic dance music venues.
ArticleMDMA
Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011-2014.
ArticleMDMA